First Time Loading...

Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 34 550 KRW 1.47% Market Closed
Updated: May 16, 2024
Section:
 

Relative Value

The Relative Value of one Hanmi Science Co Ltd stock under the Base Case scenario is 28 692.27 KRW. Compared to the current market price of 34 550 KRW, Hanmi Science Co Ltd is Overvalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
28 692.27 KRW
Overvaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
92
vs Industry
57
Median 3Y
2.4
Median 5Y
3
Industry
2.5
More Details
20.3
P/E
P/E
Price to Earnings
20.3
vs History
96
vs Industry
25
Median 3Y
41.8
Median 5Y
67.9
Industry
23.4
More Details
66.6
P/OCF
P/OCF
Price to OCF
66.6
vs History
87
vs Industry
6
Median 3Y
180.1
Median 5Y
197.2
Industry
17.9
More Details
80.7
P/FCFE
P/FCFE
Price to FCFE
80.7
vs History
82
vs Industry
8
Median 3Y
213.7
Median 5Y
198.9
Industry
24.1
More Details
3
P/B
P/B
Price to Book Value
3
vs History
77
vs Industry
27
Median 3Y
3.6
Median 5Y
3.9
Industry
2.1
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
93
vs Industry
53
Median 3Y
2.6
Median 5Y
3
Industry
2.6
More Details
10.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.7
vs History
95
vs Industry
20
Median 3Y
15.7
Median 5Y
22
Industry
5.2
More Details
38.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
38.3
vs History
96
vs Industry
8
Median 3Y
83.5
Median 5Y
89.3
Industry
13.9
More Details
44.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
44.2
vs History
96
vs Industry
9
Median 3Y
99.9
Median 5Y
114.7
Industry
17.5
More Details
71.7
EV/OCF
EV/OCF
Enterprise Value to OCF
71.7
vs History
87
vs Industry
6
Median 3Y
183.3
Median 5Y
199.8
Industry
16.4
More Details
95.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
95.1
vs History
88
vs Industry
6
Median 3Y
262.7
Median 5Y
255.9
Industry
18.1
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
92
vs Industry
35
Median 3Y
2.7
Median 5Y
3.2
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hanmi Science Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hanmi Science Co Ltd
KRX:008930
2.3T KRW 1.9 20.3 38.3 44.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
748B USD 20.8 121.9 59.6 67.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.6 45.5 34 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.4B USD 4.3 9.5 11.8 15.4
US
Merck & Co Inc
NYSE:MRK
333.6B USD 5.4 144.7 36 58.8
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.4
CH
Novartis AG
SIX:NOVN
181.5B CHF 3.4 11.5 8.7 12.8
CH
Roche Holding AG
SIX:ROG
188.5B CHF 3.2 16.4 9.3 11
US
Pfizer Inc
NYSE:PFE
162.7B USD 3 -526.6 13 20.7
P/E Multiple
Earnings Growth
KR
Hanmi Science Co Ltd
KRX:008930
Average P/E: 50.9
20.3
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
121.9
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.5
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-20%
US
Merck & Co Inc
NYSE:MRK
144.7
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Novartis AG
SIX:NOVN
11.5
15%
CH
Roche Holding AG
SIX:ROG
16.4
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -526.6
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.